XML 47 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Narrative) (Details)
In Thousands, except Share data, unless otherwise specified
12 Months Ended 12 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2014
ILS
Dec. 31, 2013
ILS
Dec. 31, 2014
Original Pipeline Funding Agreement [Member]
USD ($)
Dec. 31, 2014
Amended Pipeline Funding Agreement [Member]
USD ($)
Dec. 31, 2014
Termination and Equity Conversion Agreement [Member]
ILS
Dec. 31, 2014
Minimum [Member]
Amended Pipeline Funding Agreement [Member]
USD ($)
Dec. 31, 2014
Maximum [Member]
Amended Pipeline Funding Agreement [Member]
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Consideration received in funding arrangement           $ 5,000us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_OriginalPipelineFundingAgreementMember
       
Funding receivable           8,000cgen_ResearchAndDevelopmentArrangementReceivable
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_OriginalPipelineFundingAgreementMember
       
Options issued to agent           100,000us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_OriginalPipelineFundingAgreementMember
       
Warrant and option issuance costs           80us-gaap_PaymentOfFinancingAndStockIssuanceCosts
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_OriginalPipelineFundingAgreementMember
       
Change in fair value of liability with respect to outstanding options to non-employee    104us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss 20us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss              
Right to exchange the Amended Participation Rights for ordinary shares, calculation description             (i) $ 13,000 less 50% of any cash consideration paid to Baize as Amended Participation Rights, divided by (ii) the average closing price of the Company’s ordinary shares during the twenty (20) trading days prior to the Actual Exchange Date (the “Exchange Price”)      
Participation Rights             10.00%cgen_ParticipationRights
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
5.00%cgen_ParticipationRights
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_TerminationAndEquityConversionAgreementMember
   
Price at which investors can exchange rights             $ 7.50us-gaap_OptionIndexedToIssuersEquityStrikePrice1
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
  $ 3.00us-gaap_OptionIndexedToIssuersEquityStrikePrice1
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
$ 12.00us-gaap_OptionIndexedToIssuersEquityStrikePrice1
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
Ordinary shares eligible for purchase with warrants             500,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
     
Exercise price of warrants             $ 6.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
     
Number of shares to be issued upon exchange of Participation Rights             500,000us-gaap_OptionIndexedToIssuersEquityShares
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_AmendedPipelineFundingAgreementMember
     
Financial income (expenses) related to embedded derivative 269us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet (811)us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet (588)us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet              
Researhc and development component 421cgen_LiabilitiesArisingFromParticipationRights 758cgen_LiabilitiesArisingFromParticipationRights                
Amortization research and development component 337cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement 230cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement 130cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement              
Issuance of shares in respect to Termination and Equity Conversion Agreement, shares               1,600,000cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_TerminationAndEquityConversionAgreementMember
   
Ordinary shares, par value per share       0.01us-gaap_CommonStockParOrStatedValuePerShare 0.01us-gaap_CommonStockParOrStatedValuePerShare     0.01us-gaap_CommonStockParOrStatedValuePerShare
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= cgen_TerminationAndEquityConversionAgreementMember
   
Financial expenses as a result of 2014 Baize Agreement $ 792cgen_GainLossInRespectToTerminationAndEquityConversionAgreement                    
Agreement, start date           Sep. 20, 2010 Apr. 21, 2013 Aug. 20, 2014    
Agreement, termination date           Apr. 21, 2013 Aug. 20, 2014